3,500 Shares in IDEXX Laboratories, Inc. $IDXX Bought by Union Savings Bank

Union Savings Bank acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 3,500 shares of the company’s stock, valued at approximately $2,368,000. IDEXX Laboratories makes up approximately 1.0% of Union Savings Bank’s investment portfolio, making the stock its 17th biggest holding.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. SHP Wealth Management purchased a new stake in shares of IDEXX Laboratories in the 4th quarter worth about $26,000. Virtus Advisers LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth about $26,000. Park Place Capital Corp purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $29,000. WealthCollab LLC purchased a new position in IDEXX Laboratories during the 2nd quarter valued at about $30,000. Finally, Caitong International Asset Management Co. Ltd bought a new stake in IDEXX Laboratories during the third quarter worth about $36,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $562.09 on Friday. The company has a market capitalization of $44.34 billion, a price-to-earnings ratio of 41.39, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The company’s 50-day moving average is $561.66 and its 200 day moving average is $620.91.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The business had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same period in the previous year, the company earned $2.91 earnings per share. The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 14.68 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Stifel Nicolaus cut their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, June 13th. UBS Group cut their price target on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Finally, Citigroup began coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.